Replimune (REPL) Stock Surges After FDA Accepts RP1 Drug Resubmission | Biotech News
Introduction Replimune Group Inc. (NASDAQ: REPL) has captured investors’ attention today as its stock price surged sharply following major regulatory ... Read more